The Genitourinary (GU) Cancer Program is a multi-disciplinary program focused on the pathogenesis, diagnosis, prevention and treatment of genitourinary malignancies. While the emphasis on this Program has been and will continue to be on bladder and prostate cancers (the most common genitourinary malignancies), we are developing increasing emphasis in renal and testicular cancer as well. The scientific goal of the molecular aspects of genitourinary cancer progression and to translate discoveries into novel diagnostic and therapeutic strategies; (c) to examine the epidemiology of genitourinary cancer in order to develop hypotheses regarding possible causation, molecular etiology, and novel prevention strategies; and (d) to develop and test new surgical, chemotherapeutic, radiotherapeutic, biologic and combined modality approaches to the treatment of genitourinary cancer. These goals are being addressed through our considerable strengths in epidemiology, basic research, translational research, and clinical investigation. The GU Program which was newly proposed in the previous grant cycle, now contains 26 members from eight departments. The Program is supported by 29 peer-reviewed research projects (up from eight peer- reviewed research grants in the previous application) from 14 principal investigators. Funding totals are now over $4.7 million in direct costs annually, and a large proportion of the funded grants are multi- disciplinary. The GI Program is directly supported by the Cancer Center Core Facilities, including major involvement with Biostatistics and Cancer Research Informatics Core Facilities. The Cancer Center also fosters interaction in the GU Program through sponsorship of monthly meetings of the GU Group, GU focused Cancer Center Grand Rounds, and GU Retreats. Thus, the GU Program is an integral and well-integrated part of the USC/Norris Comprehensive Cancer Center.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA014089-26
Application #
6457507
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
1980-04-01
Project End
2005-11-30
Budget Start
Budget End
Support Year
26
Fiscal Year
2001
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Type
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Liu, Minmin; Zhang, Lian; Li, Hongtao et al. (2018) Integrative Epigenetic Analysis Reveals Therapeutic Targets to the DNA Methyltransferase Inhibitor Guadecitabine (SGI-110) in Hepatocellular Carcinoma. Hepatology 68:1412-1428
Miller, Kimberly A; Ramirez, Cynthia N; Wojcik, Katherine Y et al. (2018) Prevalence and correlates of health information-seeking among Hispanic and non-Hispanic childhood cancer survivors. Support Care Cancer 26:1305-1313
Belic, Jelena; Graf, Ricarda; Bauernhofer, Thomas et al. (2018) Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide. Int J Cancer 143:1236-1248
Tobin, Jessica; Allem, Jon-Patrick; Slaughter, Rhona et al. (2018) Posttraumatic growth among childhood cancer survivors: Associations with ethnicity, acculturation, and religious service attendance. J Psychosoc Oncol 36:175-188
Schaal, Justin B; Maretzky, Thorsten; Tran, Dat Q et al. (2018) Macrocyclic ?-defensins suppress tumor necrosis factor-? (TNF-?) shedding by inhibition of TNF-?-converting enzyme. J Biol Chem 293:2725-2734
Iriondo, Oihana; Liu, Yarong; Lee, Grace et al. (2018) TAK1 mediates microenvironment-triggered autocrine signals and promotes triple-negative breast cancer lung metastasis. Nat Commun 9:1994
Robison, Nathan J; Yeo, Kee Kiat; Berliner, Adrian P et al. (2018) Phase I trial of dasatinib, lenalidomide, and temozolomide in children with relapsed or refractory central nervous system tumors. J Neurooncol 138:199-207
Naseem, Madiha; Barzi, Afsaneh; Brezden-Masley, Christine et al. (2018) Outlooks on Epstein-Barr virus associated gastric cancer. Cancer Treat Rev 66:15-22
Sebio, A; Stintzing, S; Heinemann, V et al. (2018) A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials. Pharmacogenomics J 18:43-48
Peres, Lauren C; Risch, Harvey; Terry, Kathryn L et al. (2018) Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies. Int J Epidemiol 47:460-472

Showing the most recent 10 out of 842 publications